Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Lys3-GHRP-6
- Development stage
- Preclinical
- Lead developer
- National Institute on Aging
- Modality
- Peptides, Small Molecules
- Administration
- Intraperitoneal, Intranasal
01
Overview
D-Lys3-GHRP-6 is a **synthetic peptide antagonist of the growth hormone secretagogue receptor 1a (GHS-R1a, also known as the ghrelin receptor)**. It was developed as a modified derivative of GHRP-6, replacing alanine with D-lysine at position 3, to reverse the action from agonist to antagonist. D-Lys3-GHRP-6 is used extensively in research to inhibit ghrelin signaling both in vitro and in vivo[2][3][7]. It not only blocks GHS-R1a but also possesses weak antagonistic activity at melanocortin receptors and partial antagonist activity at several GPCRs, including CCR5 and CXCR4 chemokine receptors[3][2][7]. Its effects in animal models include decreased energy intake, altered gastric emptying, reduction of GH secretion, and modulation of behaviors linked to food, ethanol reward, and impulsivity[1][3][5][8]. Research interest has centered on its potential roles in disorders of metabolism, addiction, behavior, and as a research tool in immunology and endocrinology. The compound is not approved for any human therapeutic indications and is intended for laboratory research use.
- Other names
- [D-Lys3]-GHRP-6
02
Targets
CCR5 (C-C chemokine receptor type 5)CXCR4 (C-X-C motif chemokine receptor 4)GHSR (Growth hormone secretagogue receptor)MCR (Melanocortin receptor family)
Beyond the preview
Go deeper on D-Lys3-GHRP-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-Lys3-GHRP-6.